Abstract 195P
Background
Ferroptosis is a type of programmed cell death dependent on iron metabolism distinct from necrosis and apoptosis. In pancreatic ductal adenocarcinomas (PDAC), studies have noted that ferroptosis signatures are also associated with survival. However, no studies have attempted to find histological correlates which might suggest a ferroptosis process occurring.
Methods
PDACs from the Cancer Genome Atlas (TCGA) Pan-Cancer were used. Clinicopathological, DNA, histological slides, and mRNA expression data were extracted with the GDC Data Transfer Tool. A scree plot was generated to determine the optimal number of clustering groups based on ferroptosis molecular signatures. A K-means clustering approach was used in STATA. Groups of less than 5 patients were excluded. The ferroptosis-based clusters were correlated to clinical, histological, molecular, and survival parameters. Gene Set Enrichment Analysis (GSEA) was also performed by identified cluster. An adjusted α = 0.05 for statistical significance was used for all tests.
Results
175 PDAC cases were used from the TCGA. Optimal K-means clustering identified 4 distinct ferroptosis signature-based PDAC groups, which differed in gene expression. Group 1 (n=47) showed improved overall survival by log-rank analysis versus other 3 groups (p<0.05). There was no significant difference in age, sex distribution, tumor grade, necrosis or staging between Group 1 and other groups. Over-expressed genes in ferroptosis-based group 1 include MAP3K14, TNFAIP3, CYGb; underexpressed genes in Group 1 include EMC2, ZFAS1, CYP4F8. GSEA showed downregulation of EET, DHET and HETE synthesis, and upregulation of RNA metabolism, cell cycle and mitotic activity in Group 1 vs other 3 groups.
Conclusions
A comprehensive multimodal approach to ferroptosis expression signatures highlights a clinical impact on overall survival. However, after post-hoc analysis by two pathologists, no histological marker was identified to be significantly associated with ferroptosis signatures. Genes involved in group 1 modulate nF-κB signaling, target lipid peroxidation, and inhibit GPX4 function. Further ancillary testing of ferroptosis pathway in PDACs is warranted.
Editorial acknowledgement
Legal entity responsible for the study
Vincent Quoc-Huy Trinh.
Funding
Fonds de recherche Santé Québec.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
298P - Managing locally advanced cervical cancer: Insights from a tertiary care center and a 3-year follow-up on outcomes
Presenter: Ambedkar Yadala
Session: Poster Display
Resources:
Abstract
299P - Sexual dysfunction assessment in longterm survivors of carcinoma cervix using LENT SOMA scale
Presenter: Niharika Sethi
Session: Poster Display
Resources:
Abstract
300P - Assessing ovarian function in Vietnamese cervical cancer patients who underwent ovary transposition prior to pelvic radiation therapy
Presenter: Cuong Nguyen
Session: Poster Display
Resources:
Abstract
301P - Correlation between cervical cancer recurrence after radiation therapy and vaginal microbiome
Presenter: Xiaoxian Xu
Session: Poster Display
Resources:
Abstract
302P - Expression of ERCC4 gene and its correlation with clinical and pathological parameters in cervical cancer
Presenter: Himanshu Mishra
Session: Poster Display
Resources:
Abstract
303P - Prognostic value of body composition and systemic inflammatory markers in patients with locally advanced cervical cancer following chemoradiotherapy
Presenter: Hui Guo
Session: Poster Display
Resources:
Abstract
305P - A real-world multicenter cohort study of lenvatinib (LEN) plus pembrolizumab (PEM) in Japanese patients with endometrial cancer: Interim analysis of GOGO-EM4 study
Presenter: Yoshikazu Nagase
Session: Poster Display
Resources:
Abstract
306P - Adjuvant treatment and impact on relapse in stage IA uterine papillary serous and clear cell carcinomas: A single center retrospective study
Presenter: Sachin Khurana
Session: Poster Display
Resources:
Abstract
307P - Hormonal therapy vs combination chemotherapy in metastatic leiomyosarcomas: A systematic review
Presenter: Patricia Angel
Session: Poster Display
Resources:
Abstract
309P - Expression of estrogen receptor is a negative predictive biomarker for immunotherapy with lenvatinib plus pembrolizumab for advanced endometrial cancer with pMMR
Presenter: Hiroyuki Fujii
Session: Poster Display
Resources:
Abstract